Press Release Sosei Heptares’ Oral, Selective M4 Receptor Agonist Advancing Into Phase 2 Clinical Development Under Multi Program Collaboration With Neurocrine Biosciences
Search Related Content
Sorry, Your Requested Page Was Not Found. Greetings! We apologize for the inconvenience, but the page, Press Release Sosei Heptares’ Oral, Selective M4 Receptor Agonist Advancing Into Phase 2 Clinical Development Under Multi Program Collaboration With Neurocrine Biosciences is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3-18 months after their creation date. We prefer to keep content fresh and current, rather than holding onto outdated news. Thanks for visiting today.Search RobinsPost News & Noticias
Sosei Heptares Doses First Subject in Phase I Trial with HTL0048149, a First-in-Class GPR52 Agonist for Schizophrenia
HTL’149 has been designed as a once-daily oral treatment to address positive and negative symptoms and cognitive impairment in schizophrenia patients without the adverse effects typically associated ... Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus